SCHEDULE: Octagon Capital Discloses 5.4% Stake in Corbus Pharma

Octagon Capital Advisors LP, along with Octagon Investments Master Fund LP and Ting Jia, reported a 5.4% beneficial ownership stake in Corbus Pharmaceuticals Holdings, Inc. as of December 31, 2025.

Summary

• Octagon Capital Advisors LP, Octagon Investments Master Fund LP, and Ting Jia collectively reported beneficial ownership of 955,000 shares of Corbus Pharmaceuticals Holdings, Inc. common stock.
• This represents 5.4% of the outstanding common shares of Corbus Pharmaceuticals Holdings, Inc.
• The ownership is shared, with all 955,000 shares having shared voting and shared dispositive power among the reporting persons.
• The percentage is calculated based on 17,553,037 common shares outstanding as of November 7, 2025, as reported in the Issuer's Form 10-Q filed on November 12, 2025.
• The securities were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of the issuer.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as moderately positive. The disclosure of a significant institutional stake by Octagon Capital Advisors suggests a vote of confidence in Corbus Pharmaceuticals, which can be a positive signal for other investors.

Positives

• A significant institutional investor, Octagon Capital Advisors LP, has disclosed a 5.4% stake in Corbus Pharmaceuticals Holdings, Inc., indicating confidence in the company.
• The investment is stated to be in the ordinary course of business, suggesting a long-term investment strategy rather than an activist play.

Future Outlook

NA

Management Comments

• "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11."

Industry Context

StockSavvy.ai notes that the disclosure of a significant institutional stake by Octagon Capital Advisors in Corbus Pharmaceuticals Holdings, Inc. is a common occurrence in the biotechnology and pharmaceutical sectors. Such filings often signal institutional confidence in a company's pipeline or strategic direction, potentially attracting further investor interest. This type of passive investment, as indicated by the 13G filing, suggests a belief in the company's long-term value without immediate intentions of influencing management or control.

Comparison to Industry Standards

• A 5.4% stake by an investment fund like Octagon Capital Advisors is a notable position, often considered a significant vote of confidence in a small to mid-cap biotechnology company like Corbus Pharmaceuticals.
• For example, similar institutional holdings are seen in other emerging biotech firms where funds like ARK Invest or BlackRock often take substantial passive stakes, such as ARK's holdings in Exact Sciences (EXAS) or BlackRock's positions in smaller pharmaceutical innovators.
• While not an activist stake, it places Octagon among the larger institutional holders, comparable to early-stage venture capital or specialized healthcare funds that build positions in companies with promising drug candidates or technology platforms.

Related Party Transactions

• Octagon Capital Advisors LP serves as the investment manager of Octagon Investments Master Fund LP.
• Ting Jia is the managing member of Octagon Capital Advisors LP and is deemed the principal beneficial owner of Octagon.
• By virtue of these relationships, Octagon Capital Advisors LP and Ting Jia may be deemed to beneficially own the shares held by the Master Fund.

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional investor holding a 5.4% stake may instill greater confidence and potentially attract further investment, positively impacting share price.
• Management: The presence of a large institutional holder, even a passive one, can lead to increased scrutiny and expectations regarding company performance and strategic execution.

Next Steps

• The reporting persons will be required to file an amendment to this Schedule 13G if their beneficial ownership percentage changes significantly (e.g., drops below 5% or increases substantially) or if their investment intent changes from passive to active.

Key Dates

Recommendation

The filing indicates a significant institutional investor has taken a 5.4% stake, which is generally a positive signal of confidence in the company's long-term prospects. However, a Schedule 13G filing itself does not provide new operational or financial performance data to warrant a "buy" or "sell" recommendation. It primarily confirms institutional interest. Therefore, a "hold" recommendation is appropriate, suggesting investors maintain their current positions while monitoring future company developments and financial reports for more substantive catalysts.

Keywords

Corbus Pharmaceuticals, Octagon Capital Advisors, Octagon Investments Master Fund, Ting Jia, Beneficial Ownership, Schedule 13G, Institutional Investor, Common Stock, Biotechnology, Pharmaceuticals